PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |

efavirenz

  • efavirenz has not been evaluated in the literature showing its role of altering the activities of CYP2C9 and CYP2C19.
  • CYP2C9CYP2C19
    Not evaluated in the literatureatazanavir
    efavirenz
    5-fluorouracil
    fluoxetine
    imatinib
    isoniazid
    leflunomide
    phenobarbitone
    phenytoin
    ritonavir
    teniposide
    efavirenz [a]
    indomethacin
    modafinil
    oxcarbazepine
    phenobarbitone
    phenytoin
    prednisone

    Footnotes and References

    a.poster found at http://www.klinikum.uni-heidelberg.de/fileadmin/medizinische_klinik/Abteilung_6/pdf/Posterpreis_VKliPha2008_Bayer.pdf
    Disclaimer
    WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.